Press release
Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033 | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size
The Business Research Company offers in-depth market insights through Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.
The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Market Segmentation:
The main types of forms of chemotherapy-induced nausea and vomiting (CINV) are injectables, oral and transdermal patches. Injectables are chemicals that are injected into the body to have various effects. The various drug classes are 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids and others and various emetogenic risks are highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC). The various distribution channels are CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies and drug stores applied in gynecology, urology, gastrointestinal surgery and others.
Major Driver - Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market
The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has led to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, it is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) market.
Competitive Landscape:
Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report
Top Trend - Leading Companies In The Cinv Market Pioneering Transdermal Delivery System (TDS) Innovations
Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as transdermal delivery systems (TDS), to meet the customer requirements in the market. A transdermal delivery system (TDS) is a drug delivery system that allows the controlled release of a medication through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a US-based biotechnology company, announced the FDA approval for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) covering the duration of the five-day CINV therapy. Independent double-blind trials have revealed that olanzapine is a potent antiemetic, outperforming other standard-of-care therapies, including NK1 receptor antagonists, regarding nausea management. STAR-OLZ previously completed Phase 1 in-human bioavailability (BA) trials, demonstrating that the transdermal patch has acceptable local tolerability during a 5-day dosing interval and provides roughly 60% less medication than the oral version.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics
3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies
4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario
5. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size And Growth
…..
27. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The chemotherapy-induced nausea and vomiting (cinv) market size has grown strongly in recent years. It will grow from $2.69 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growth in chemotherapy use, improved antiemetic agents, clinical guidelines, patient advocacy.
The chemotherapy-induced nausea and vomiting (cinv) market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to personalized medicine, advances in antiemetic agents, telehealth and remote monitoring, health equity initiatives. Major trends in the forecast period include combination antiemetic therapies, supportive care services, digital health tools, survivorship care.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13031&type=smp
Market Segmentation:
The main types of forms of chemotherapy-induced nausea and vomiting (CINV) are injectables, oral and transdermal patches. Injectables are chemicals that are injected into the body to have various effects. The various drug classes are 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, corticosteroids, cannabinoids and others and various emetogenic risks are highly emetogenic chemotherapy (HEC), moderately emetogenic chemotherapy (MEC) and low emetogenic chemotherapy (LEC). The various distribution channels are CINV hospitals, cancer research institutes, retail pharmacies, online pharmacies and drug stores applied in gynecology, urology, gastrointestinal surgery and others.
Major Driver - Rising Cancer Prevalence Spurs Growth In The Chemotherapy-Induced Nausea And Vomiting (CINV) Market
The increasing prevalence of cancer is expected to propel the growth of chemotherapy-induced nausea and vomiting (CINV) market going forward. Cancer is when some cells in the body develop uncontrolled and spread to other body regions. As cancer cases continue to grow, there is a greater incentive to develop more effective and targeted anti-emetic treatments to alleviate CINV, a distressing side effect of chemotherapy. This heightened focus on CINV management has led to advancements in understanding its underlying mechanisms and developing novel therapies. For instance, in January 2023, according to the American Cancer Society (ACS), a US-based volunteer health organization committed to cancer eradication, in the United States, it is anticipated to be 1.9 million new cancer cases (approximately 5,370 cases per day) and 609,820 cancer deaths (about 1,670 deaths per day) in 2023. Therefore, the increasing prevalence of cancer will drive the chemotherapy-induced nausea and vomiting (CINV) market.
Competitive Landscape:
Major players in the chemotherapy-induced nausea and vomiting (cinv) market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Baxter International Inc., Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Jazz Pharmaceuticals PLC, Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Kyowa Kirin Inc., Amneal Pharmaceuticals Inc., Mundipharma International Limited, Insys Therapeutics Inc., Lupin Limited, Helsinn Holding S.A., Heron Therapeutics Inc., Camurus AB, Cadila Pharmaceuticals Limited, Acacia Pharma Ltd., Soligenix Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-nausea-and-vomiting-cinv-global-market-report
Top Trend - Leading Companies In The Cinv Market Pioneering Transdermal Delivery System (TDS) Innovations
Major companies operating in the chemotherapy-induced nausea and vomiting (CINV) market are working on new product innovations, such as transdermal delivery systems (TDS), to meet the customer requirements in the market. A transdermal delivery system (TDS) is a drug delivery system that allows the controlled release of a medication through the skin for systemic absorption. For instance, in April 2021, Starton Therapeutics Inc., a US-based biotechnology company, announced the FDA approval for STAR-OLZ transdermal delivery system (TDS) to treat chemotherapy-induced nausea and vomiting (CINV). STAR-OLZ is a multi-day olanzapine transdermal delivery system (TDS) covering the duration of the five-day CINV therapy. Independent double-blind trials have revealed that olanzapine is a potent antiemetic, outperforming other standard-of-care therapies, including NK1 receptor antagonists, regarding nausea management. STAR-OLZ previously completed Phase 1 in-human bioavailability (BA) trials, demonstrating that the transdermal patch has acceptable local tolerability during a 5-day dosing interval and provides roughly 60% less medication than the oral version.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Characteristics
3. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Trends And Strategies
4. Chemotherapy-Induced Nausea and Vomiting (CINV) Market - Macro Economic Scenario
5. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size And Growth
…..
27. Chemotherapy-Induced Nausea and Vomiting (CINV) Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy-Induced Nausea and Vomiting (CINV) Global Market Report 2024: Key Players, Demand Patterns And Forecasts 2033 | Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc here
News-ID: 3405202 • Views: …
More Releases from The Business Research Company
Managed Print Services Market Size, Share, Trends 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Managed Print Services Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $14.61 billion In 2028…
Automotive Adhesives Market 2024: Key Growth Drivers and Industry Insights
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Automotive Adhesives Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $7.49 billion In 2028 At…
Wear Parts Market Size, Growth Analysis, Trends And Forecast 2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wear Parts Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $796.11 billion In 2028 At…
Assured Positioning, Navigation, And Timing (PNT) Market Report 2024: Market Siz …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Assured Positioning, Navigation, And Timing (PNT) Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.94…
More Releases for CINV
CINV Existing and Pipeline Drugs Market: Rising Demand for CINV Drugs Owing to I …
CINV drugs are administered to patients suffering from vomiting and nausea that occurs as a side effect of chemotherapy. CINV can hinder the progress of patients undergoing chemotherapy, making it very crucial for oncologists to prescribe the right kind of CINV drugs to alleviate the discomfort. Delayed CINV and acute CINV are the two major subtypes of this condition. While the former occurs up to five days after treatment, the…
CINV Existing and Pipeline Drugs Market : Growing number of patients undergoing …
The growth of the global chemotherapy induced nausea and vomiting (CINV) market will be steered by the growing number of patients undergoing chemotherapy and a number of new drugs expected to be approved in the near future, says Transparency Market Research. In its report, titled “CINV Existing and Pipeline Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” the business intelligence firm says that…
Chemotherapy-induced Nausea and Vomiting (CINV) Treatment Market Analysis And Fo …
According to WHO cancer is one of the most leading causes for death with around 8 million deaths and 14 million new patients in 2012. Chemotherapy, which is received by approximately four million cancer patients each year, is among the most commonly used treatment to fight cancer. However, this mode of treatment has many side effects, an estimate of around 70% - 80% of the patients receiving chemotherapy treatment experience…
Global Cleanliness Analyser System Market 2017-Cinv, Particle Technology Limited …
In this report, the global Cleanliness Analyser System market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cleanliness Analyser System in these regions, from 2012 to 2022…
Global Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs Market Research Re …
This report studies Chemotheraphy Induced Nausea and Vomiting (CINV) Drugs in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
GlaxoSmithKline Plc
Helsinn Group
Heron Therapeutics
Merck & Co Inc
Tesaro
...
Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of…
Chemotherapy Induced Nausea and Vomiting (CINV) - Market Insights, Epidemiology …
Market Research HUB's new report "Chemotherapy Induced Nausea and Vomiting (CINV)- Market Insights, Epidemiology and Market Forecast-2023" Report provides an overview of the disease and global market size of the Chemotherapy Induced Nausea and Vomiting (CINV) in the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes historical and forecasted epidemiological data for the Incident cases of Chemotherapy-Induced Nausea and Vomiting (CINV) from 2013-2023.
Request Free…
